CME: Endometrial cancer: treatment updates and gaps in management
ACCREDITATION EXPIRED: July 09, 2022
Activity Description / Statement of Need:
In this online, self-learning activity:
Endometrial cancer, a type of cancer that originates in the lining of the uterus, is the most common gynecologic cancer and the fourth most common cancer in women living in the United States, with over 66,000 cancers of the uterine corpus diagnosed every year and 13,000 associated deaths. The vast majority of women are diagnosed with endometrial cancer after the age of 50, and risk factors are obesity, level of physical activity, increasing age, and the presence of a variety of comorbid, chronic health conditions. Levels of estrogen and progesterone fluctuate during the menstrual cycle, resulting in cell proliferation and differentiation that may lead to abnormalities that contribute to malignancies later in life. The costs associated with endometrial cancer may amount to tens of thousands of dollars per patient, depending on the stage of disease upon diagnosis.
This activity has been designed to bring HCP's knowledge of identification, management, and patient care strategies for endometrial cancer up to date and to improve their competence and performance in treating the disease.
Target Audience:
The following HCPs: Medical oncologists and pathologists; physician assistants, nurse practitioners, and pharmacists who practice in oncology; and other clinicians who commonly encounter patients with endometrial cancer.
Commercial Support Disclosure: This program is supported by an educational grant from Merck.
This activity is free of charge.
Release Date: July 09, 2021 -- Expiration Date: July 09, 2022
Faculty: Dario Roque, MD
Agenda
|
Faculty introduction, disclosures |
|
Introduction content: review of endometrial cancer
|
|
Treatment of endometrial cancer with a focus on advanced and recurrent disease
· Chemotherapy-naïve patients · Disease recurrence · Mismatch repair-deficient · Microsatellite-instable · High tumor mutational burden
· Adverse effect identification and management [Learning objective #s 3 & 4] · Gaps in care and modifiable healthy equity challenges [Learning objective #5]
|
|
Summary, conclusions, and best practice recap |
Learning Objectives
By the end of the session the participant will be able to:
- Recall the challenges in the diagnosis of endometrial cancer and their impact on outcomes.
- Describe the role of biomarker/molecular testing in determining the prognosis and treatment of endometrial cancer.
- List evidence-based treatment considerations and emerging therapies in the clinical management of endometrial cancer.
- Formulate a treatment plan for a patient with endometrial cancer.
- Discuss challenges and modifiable health equity factors associated with treating subpopulations of patients with endometrial cancer.
Accreditation
ACCME Activity #201748771
ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.Faculty Disclosure and Resolution of COI
As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.
Faculty Disclosure: Dario R. Roque, MD, Assistant Professor, Division of Gynecologic Oncology, Northwestern University Feinberg School of Medicine, has received financial compensation for the following: Speaker’s Bureau from GSK and Merck; Advisory Panel from Myriad; and Surgical Proctor from Intuitive Surgical.
Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant financial disclosures.
All relevant financial relationships have been mitigated.
ScientiaCME adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Commercial Support Disclosure: This program is supported by an educational grant from Merck.
Instructions
- Read the learning objectives above
- Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
- View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
- Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
- Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.
System Requirements
Windows 7 or above
Internet Explorer 8
*Adobe Acrobat Reader
Mac OS 10.2.8
Safari or Chrome or Firefox
*Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh
*Required to view Printable PDF Version
Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.
Additional Courses That Are Related To This Activity
Recurrent and metastatic endometrial cancer: Therapeutic updates and optimizing treatment
Biosimilars in the treatment of malignancies and supportive care
Updates in chronic lymphocytic leukemia (CLL) treatment paradigms